Search research articles
Contact Us
Filters
Showing results (41-50 of 212) with videos related to
Page
of 22
Sort By:
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
|
November 27, 2002
The risks of waiting for cardiac catheterization: a prospective study
Madhu K Natarajan, Shamir R Mehta, Douglas H Holder, et al.
American Heart Journal
|
December 1, 2012
Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy
Philippe Gabriel Steg, Shamir R Mehta, Charles V Pollack, et al.
Circulation
|
February 26, 2003
Early and late effects of clopidogrel in patients with acute coronary syndromes
Salim Yusuf, Shamir R Mehta, Feng Zhao, et al.
Diabetes Care
|
November 15, 2011
Piloting a novel algorithm for glucose control in the coronary care unit: the RECREATE (REsearching Coronary REduction by Appropriately Targeting Euglycemia) trial
Kara A Nerenberg, Abhinav Goyal, Denis Xavier, et al.
American Heart Journal
|
December 22, 2005
A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions
Madhu K Natarajan, James L Velianou, Alexander G G Turpie, et al.
American Heart Journal
|
April 21, 2009
Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial
Mark J Sculpher, Greta Lozano-Ortega, Jennifer Sambrook, et al.
American Heart Journal
|
July 22, 2019
Design and rationale of the COMPLETE trial: A randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation myocardial infarction
Shamir R Mehta, David A Wood, Brandi Meeks, et al.
American Heart Journal
|
January 6, 2005
Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: the CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarction
Salim Yusuf, Shamir R Mehta, Rafael Díaz, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|
March 27, 2017
A laboratory score at presentation to rule-out serious cardiac outcomes or death in patients presenting with symptoms suggestive of acute coronary syndrome
Peter A Kavsak, Colleen Shortt, Jinhui Ma, et al.
Circulation
|
September 25, 2002
Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups
Andrzej Budaj, Salim Yusuf, Shamir R Mehta, et al.
Page
of 22
Search research articles
Search
Showing results (41-50 of 212) with videos related to
Sort By:
Page
of 22
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
|
November 27, 2002
The risks of waiting for cardiac catheterization: a prospective study
Madhu K Natarajan, Shamir R Mehta, Douglas H Holder, et al.
American Heart Journal
|
December 1, 2012
Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy
Philippe Gabriel Steg, Shamir R Mehta, Charles V Pollack, et al.
Circulation
|
February 26, 2003
Early and late effects of clopidogrel in patients with acute coronary syndromes
Salim Yusuf, Shamir R Mehta, Feng Zhao, et al.
Diabetes Care
|
November 15, 2011
Piloting a novel algorithm for glucose control in the coronary care unit: the RECREATE (REsearching Coronary REduction by Appropriately Targeting Euglycemia) trial
Kara A Nerenberg, Abhinav Goyal, Denis Xavier, et al.
American Heart Journal
|
December 22, 2005
A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions
Madhu K Natarajan, James L Velianou, Alexander G G Turpie, et al.
American Heart Journal
|
April 21, 2009
Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial
Mark J Sculpher, Greta Lozano-Ortega, Jennifer Sambrook, et al.
American Heart Journal
|
July 22, 2019
Design and rationale of the COMPLETE trial: A randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation myocardial infarction
Shamir R Mehta, David A Wood, Brandi Meeks, et al.
American Heart Journal
|
January 6, 2005
Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: the CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarction
Salim Yusuf, Shamir R Mehta, Rafael Díaz, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|
March 27, 2017
A laboratory score at presentation to rule-out serious cardiac outcomes or death in patients presenting with symptoms suggestive of acute coronary syndrome
Peter A Kavsak, Colleen Shortt, Jinhui Ma, et al.
Circulation
|
September 25, 2002
Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups
Andrzej Budaj, Salim Yusuf, Shamir R Mehta, et al.
Page
of 22